Prediction of MACE After ACS

Current prevention of major adverse cardiovascular events (MACE) after acute coronary syndromes (ACS) is based on aggressive medical therapy, and guideline-driven treatment of traditional coronary risk factors. These include achieving low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure, and glycosylated hemoglobin target levels, smoking cessation, and physical activity. In patients with left ventricular ejection fraction below 40%, the use of an angiotensin-converting enzyme inhibitor is recommended, and in patients with left ventricular ejection fraction below 35% an automatic implantable cardioverter-defibrillator should be considered (2).